Gain TherapeuticsGANX
GANX
About: Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Employees: 25
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
150% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 4
104% more call options, than puts
Call options by funds: $47K | Put options by funds: $23K
32% more funds holding
Funds holding: 19 [Q3] → 25 (+6) [Q4]
0.92% more ownership
Funds ownership: 6.56% [Q3] → 7.48% (+0.92%) [Q4]
21% less capital invested
Capital invested by funds: $9.77M [Q3] → $7.68M (-$2.09M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
233%
upside
Avg. target
$8.67
381%
upside
High target
$12
567%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Keay Nakae 13% 1-year accuracy 9 / 72 met price target | 233%upside $6 | Buy Maintained | 28 Mar 2025 |
HC Wainwright & Co. Raghuram Selvaraju 30% 1-year accuracy 99 / 335 met price target | 344%upside $8 | Buy Reiterated | 17 Mar 2025 |
Scotiabank Louise Chen 19% 1-year accuracy 23 / 120 met price target | 567%upside $12 | Sector Outperform Initiated | 7 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that a poster detailing the design of the Phase 1b clinical trial of GT-02287 in Parkinson's disease will be presented at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria.
Neutral
GlobeNewsWire
3 weeks ago
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025 First Analysis from Phase 1b Study of GT-02287 in Parkinson's Disease Expected in Q2 2025
Neutral
GlobeNewsWire
1 month ago
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
BETHESDA, Md., March 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the dosing of the first participant with Parkinson's disease (PD) in its Phase 1b clinical trial of GT-02287, the Company's lead allosteric small molecule in development for the treatment of PD with or without a GBA1 mutation.
Neutral
GlobeNewsWire
1 month ago
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
BETHESDA, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Joanne Taylor, Ph.D., Senior Vice President of Research at Gain, will give an oral presentation on the Company's clinical stage lead drug candidate GT-02287 at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders. AD/PD™ 2025 is being held April 1-5, 2025, in Vienna, Austria.
Neutral
GlobeNewsWire
2 months ago
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company's President and CEO, Gene Mack:
Neutral
GlobeNewsWire
2 months ago
Gain Therapeutics To Participate in Upcoming Investor Conferences
BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Executive Officer of Gain, will present at two upcoming investor conferences:
Positive
Zacks Investment Research
3 months ago
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy
Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
3 months ago
Best Momentum Stocks to Buy for January 9th
GANX, FHB and TRV made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 9, 2024.
Positive
Seeking Alpha
3 months ago
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results
Gain Therapeutics' GT-02287 shows promising efficacy and safety data, targeting both idiopathic and GBA1 Parkinson's disease, with potential for substantial market impact and investor gains. The drug's ability to restore GCase function and its positive preclinical and Phase 1 results highlight its potential as a best-in-class treatment. Gain's aggressive development strategy and strong data sharing indicate confidence, with Phase 1b trial results expected by mid-2025, potentially increasing the company's valuation.
Neutral
GlobeNewsWire
3 months ago
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease
The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability along with biomarkers during three months of dosing with GT-02287 in people diagnosed with Parkinson's disease Phase 1b clinical trial follows successful Phase 1 study in which GT-02287 was safe and well tolerated while demonstrating GCase target engagement BETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced it has received approval in Australia to initiate a Phase 1b trial.
Charts implemented using Lightweight Charts™